I

t’s do-or-die time for Sage Therapeutics (SAGE).

The failure of the brexanolone phase 3 clinical trial in severe epilepsy announced Tuesday bent, but did not break, Sage’s stock price. The company is getting a second chance to prove the therapeutic value of brexanolone with two phase 3 studies in women with postpartum depression.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X